Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
30/06/2026 12:06
BRIEF-Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data June 30 (Reuters) - Pasithea Therapeutics Corp KTTA.O:
ANNOUNCES POSITIVE INTERIM PHASE 1 ADVANCED CANCER STUDY DATA DEMONSTRATING LONG-TERM SAFETY AND TOLERABILITY, AND DURABLE CLINICAL ACTIVITY IN MEK/BRAF-PRETREATED PATIENTS, PLUS PROTOCOL EXPANSION
PAS-4 SHOWS FAVORABLE SAFETY PROFILE WITH ONLY GRADE 1 OR 2 ADVERSE EVENTS
PROTOCOL AMENDMENT EXTENDS DOSE ESCALATION UP TO 52MG FOR PAS-4
INITIATES PILOT FOOD EFFECT STUDY FOR PAS-4 PHARMACOKINETICS
Source text: ID:nGNX31bmmG
Further company coverage: KTTA.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement